WO2005041896A3 - Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke - Google Patents

Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke Download PDF

Info

Publication number
WO2005041896A3
WO2005041896A3 PCT/US2004/036495 US2004036495W WO2005041896A3 WO 2005041896 A3 WO2005041896 A3 WO 2005041896A3 US 2004036495 W US2004036495 W US 2004036495W WO 2005041896 A3 WO2005041896 A3 WO 2005041896A3
Authority
WO
WIPO (PCT)
Prior art keywords
risk
methods
stroke
perioperative
renal dysfunction
Prior art date
Application number
PCT/US2004/036495
Other languages
French (fr)
Other versions
WO2005041896A2 (en
Inventor
Debra A Schwinn
Ian Welsby
Mihai V Podgoreanu
Mark Stafford-Smith
Mark F Newman
Hilary P Grocott
William D White
Richard W Morris
Joseph P Mathew
Original Assignee
Univ Duke
Debra A Schwinn
Ian Welsby
Mihai V Podgoreanu
Mark Stafford-Smith
Mark F Newman
Hilary P Grocott
William D White
Richard W Morris
Joseph P Mathew
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke, Debra A Schwinn, Ian Welsby, Mihai V Podgoreanu, Mark Stafford-Smith, Mark F Newman, Hilary P Grocott, William D White, Richard W Morris, Joseph P Mathew filed Critical Univ Duke
Priority to EP04800614A priority Critical patent/EP1687447A4/en
Priority to CA002549971A priority patent/CA2549971A1/en
Publication of WO2005041896A2 publication Critical patent/WO2005041896A2/en
Publication of WO2005041896A3 publication Critical patent/WO2005041896A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Abstract

The present invention relates, in general, to perioperative bleeding and, in particular, to methods of identifying individuals at risk of perioperative bleeding. The present invention relates, in general, to perioperative renal dysfunction and, in particular, to methods of identifying individuals at risk of perioperative renal dysfunction. The present invention relates, in general, to perioperative stroke and, in particular, to methods of identifying individulas at risk of perioperative stroke.
PCT/US2004/036495 2003-11-03 2004-11-03 Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke WO2005041896A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP04800614A EP1687447A4 (en) 2003-11-03 2004-11-03 Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke
CA002549971A CA2549971A1 (en) 2003-11-03 2004-11-03 Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US51631303P 2003-11-03 2003-11-03
US60/516,313 2003-11-03
US56779304P 2004-05-05 2004-05-05
US60/567,793 2004-05-05
US62066604P 2004-10-22 2004-10-22
US60/620,666 2004-10-22

Publications (2)

Publication Number Publication Date
WO2005041896A2 WO2005041896A2 (en) 2005-05-12
WO2005041896A3 true WO2005041896A3 (en) 2006-02-02

Family

ID=34557381

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/036495 WO2005041896A2 (en) 2003-11-03 2004-11-03 Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke

Country Status (4)

Country Link
US (4) US7439019B2 (en)
EP (1) EP1687447A4 (en)
CA (1) CA2549971A1 (en)
WO (1) WO2005041896A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2549971A1 (en) 2003-11-03 2005-05-12 Duke University Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
CA2612859A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
WO2009041004A1 (en) * 2007-09-27 2009-04-02 Nemoto Kyorindo Co., Ltd. Chemical dosing device, radiographic system and computer program
CA2794757A1 (en) 2008-11-11 2010-05-20 Prometheus Laboratories Inc. Methods for prediction of inflammatory bowel disease (ibd) using serologic markers
EP2419529B1 (en) 2009-04-14 2015-05-20 Nestec S.A. Inflammatory bowel disease prognostics
EP2778685B1 (en) 2009-06-25 2017-04-26 Nestec S.A. Methods for diagnosing irritable bowel syndrome
WO2011060098A1 (en) 2009-11-10 2011-05-19 Prometheus Laboratories Inc. Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis
NZ609363A (en) 2010-10-18 2015-04-24 Nestec Sa Methods for determining anti-drug antibody isotypes
EP2676137B1 (en) 2011-02-17 2014-12-31 Nestec S.A. Assays for detecting autoantibodies to anti-tnf drugs
CN110544517A (en) 2011-05-10 2019-12-06 雀巢产品有限公司 Disease activity characterization method for personalized therapy management
EP2769321B1 (en) 2011-10-21 2016-06-01 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
CA2887035A1 (en) 2012-10-05 2014-04-10 Nestec S.A. Methods for predicting and monitoring mucosal healing
CN103224981A (en) * 2013-01-24 2013-07-31 武汉康圣达医学检验所有限公司 Primer group and method for detecting non-small cell lung cancer radiotherapy toxic and side effect-related polymorphic site genotype by mass-spectrography method
WO2014145705A2 (en) 2013-03-15 2014-09-18 Battelle Memorial Institute Progression analytics system
CN105392780A (en) 2013-05-24 2016-03-09 雀巢产品技术援助有限公司 Pathway specific assays for predicting irritable bowel syndrome diagnosis
EP3077818B1 (en) 2013-12-03 2020-02-05 Prometheus Biosciences, Inc. Methods for predicting post-operative recurrence of crohn's disease
WO2015166461A1 (en) 2014-05-01 2015-11-05 Nestec S.A. Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels
EP3227685A1 (en) 2014-12-02 2017-10-11 Nestec S.A. Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease
SG11202003216QA (en) 2017-10-10 2020-05-28 Prometheus Biosciences Inc Methods for monitoring vedolizumab treatment
RU2745360C1 (en) * 2020-07-20 2021-03-24 Государственное бюджетное учреждение здравоохранения "Научно-исследовательский институт - краевая клиническая больница N1 имени профессора С.В. Очаповского" Министерства здравоохранения Краснодарского края (ГБУЗ "НИИ-ККБ N1" МЗ КК) Method for predicting postsurgical complications in chest operations
CN112226494A (en) * 2020-10-21 2021-01-15 上海鼎晶生物医药科技股份有限公司 Primer group for detecting rs5186 site polymorphism of AGTR1 gene and application thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1191908A (en) 1915-03-24 1916-07-18 Frank Petrak Traction-wheel of the portable-track type.
US6686338B1 (en) 1996-02-23 2004-02-03 The Board Of Regents Of The University Of Nebraska Enzyme inhibitors for metabolic redirection
US6693052B2 (en) 1996-10-15 2004-02-17 Warwick Mills, Inc. Garment including protective fabric
GB9915939D0 (en) 1999-07-08 1999-09-08 Johnson Matthey Plc Improvements in pollution control
US6775783B1 (en) 1999-08-13 2004-08-10 Cisco Technology, Inc. Client security for networked applications
US6781754B2 (en) 2000-06-07 2004-08-24 Cirvine Corporation Interleaver using spatial birefringent elements
AU2001281318A1 (en) 2000-07-11 2002-01-30 Kirk Hogan Methods and compositions for perioperative genomic profiling
AU2002228871A1 (en) 2000-11-09 2002-05-21 Genaissance Pharmaceuticals, Inc. Haplotypes of the il6 gene
US6635181B2 (en) 2001-03-13 2003-10-21 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Continuous, hybrid field-gradient device for magnetic colloid based separations
JP2003057537A (en) 2001-08-21 2003-02-26 Pentax Corp Observation optical system provided with image blurring correcting system
CA2518957A1 (en) 2003-03-10 2004-09-23 Applera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
CA2549971A1 (en) 2003-11-03 2005-05-12 Duke University Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke
US7592141B2 (en) 2004-12-13 2009-09-22 Duke University Methods of identifying individuals at reduced risk of sepsis
WO2006116197A2 (en) 2005-04-22 2006-11-02 Duke University Methods of identifying individuals at risk of perioperative myocardial injury, major adverse cardiac events, cognitive decline, arrhythmias, depression or bleeding

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DI PAOLA J ET AL: "Low Platelet Alpha2Beta1 Levels in Type I Von Willebrand Disease Correlate with Impaired Platelet Function in a High Shear Stress System.", BLOOD., vol. 93, June 1999 (1999-06-01), pages 3578 - 3582, XP002993201 *
JACQUELIN B. ET AL: "Allele-Dependent Transcriptional Regulation of the Human Integrin Alpha2 Gene.", BLOOD., vol. 97, March 2001 (2001-03-01), pages 1721 - 1726, XP002992999 *
KRITZIK M ET AL: "Nucleotide Polymorphisms in the Alpha2 Gene Define Multiple Alleles that are Associated with Differences in Platelet Alpha2 Beta1 Density.", BLOOD., vol. 92, October 1998 (1998-10-01), pages 2382 - 2388, XP002993000 *
KUNICKI TJ ET AL: "The Influence of Platelet Collagen Receptor Polymorphisms in Hemostasis and Thrombotic Disease.", ARTERIOSCLEROSIS, THROMBOSIS & VASCULAR BIOLOGY., vol. 22, 2002, pages 14 - 20, XP002249922 *
PIVALIZZA E ET AL: "Perioperative Use of the Thrombelastograph in Patients with Inherited Bleeding Disorders.", JOURNAL OF CLINICAL ANESHTESIA., vol. 15, August 2003 (2003-08-01), pages 366 - 370, XP002993202 *
SANTORO SA ET AL: "Platelet Surface Collagen Receptor Polymorphisms: Variable Receptor Expression And Thrombotic/Hemorrhagic Risk.", BLOOD., vol. 93, June 1999 (1999-06-01), pages 3575 - 3577, XP002993203 *
See also references of EP1687447A4 *
VINCENTELLI A ET AL: "Acquired Von Willebrand Syndrome in Aortic Stenosis.", THE NEW ENGLAND JOURNAL OF MEDICINE., vol. 349, July 2003 (2003-07-01), pages 343 - 349, XP008068598 *

Also Published As

Publication number Publication date
US20060024682A1 (en) 2006-02-02
WO2005041896A2 (en) 2005-05-12
US20120322667A1 (en) 2012-12-20
US7439019B2 (en) 2008-10-21
CA2549971A1 (en) 2005-05-12
EP1687447A2 (en) 2006-08-09
US8187807B2 (en) 2012-05-29
EP1687447A4 (en) 2008-04-02
US20140141429A1 (en) 2014-05-22
US20090075271A1 (en) 2009-03-19
US9556486B2 (en) 2017-01-31

Similar Documents

Publication Publication Date Title
WO2005041896A3 (en) Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke
WO2005047471A3 (en) Improved fret efficiency methods
WO2005014850A3 (en) Systems and methods for analyzing nucleic acid sequences
WO2004099352A3 (en) Additives and methods for reducing odor
WO2005047314A3 (en) Fgf-beta binding and supported peptides
WO2004099068A3 (en) Nanofiber surfaces for use in enhanced surface area applications
WO2006017274A3 (en) Systems and methods for sample modification using fluidic chambers
WO2005087951A3 (en) Reagents, methods and kits for use in deactivating nucleic acids
AU2006272804A8 (en) Concentrated protein lyophilates, methods, and uses
AP2005003474A0 (en) Compositions and methods for increasing telomeraseactivity.
EP1623011A4 (en) IL-23p40 SPECIFIC IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
WO2004078120A3 (en) Collagen compositions and biomaterials
WO2007060117A3 (en) Chimeric keratin-binding effector proteins
WO2005116252A3 (en) Methods for evaluating ribonucleotide sequences
WO2004055117A3 (en) Carboxamide-substituted dyes for analytical applications
WO2006119494A3 (en) Acute myelogenous leukemia biomarkers
WO2005086654A3 (en) Self-cleaving affinity tags and methods of use
AU2001269575A1 (en) Nucleic acid sequences and proteins involved in cellular senescence
EP1711527A4 (en) Hla-dr-specific antibodies, compositions and methods
AU2003225976A1 (en) Anti-tnf antibodies, compositions, methods and uses
EP2757197A3 (en) Retroreflective elements and articles
WO2006074443A3 (en) Pde5 inhibitor compositions and methods for immunotherapy
WO2006017440A3 (en) Cosmetic enhancement mirror
WO2005017177A3 (en) Modulators of nod1 signaling
EP1417970A3 (en) Anti-allergic, anti-bacteric and anti-redden compound for eyes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004800614

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2549971

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2004800614

Country of ref document: EP